Resources

Type 2 diabetes is a common chronic disease. Many Australians are at risk of developing type 2 diabetes, especially if they have certain risk factors. This tool uses a brief list of questions to assess the risk of a person developing type 2 diabetes in the next 5 years.

Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 6 March 2025.

This fact sheet provides information on the national NBS decision-making pathway, including the role of each committee in the process.

This fact sheet provides information about what NBS expansion means for families and consumers, expansion progress to date, and upcoming milestones.

This report outlines the Avalglucosidase alfa 24 Month Review Terms of Reference and Protocol Questions

Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 13 December 2024.

The 2024 Annual Report gives an overview of the National Registry and summarises information notified to the National Registry in the first three months of operation and general observations. This Annual Report includes data on mandatory and voluntary notifications, exposure, occupation.

This postcard provides basic information on the National Registry such as the National Registry’s purpose, mandatory and voluntary notifications, and a link to the National Registry website for further information.

This brochure contains key information regarding the National Registry, including types of data collected, purpose of the National Registry, physician obligations, and contact details for the physician help desk. This brochure contains links to the National Registry website and the Physician Portal.

This is the government response to the interim report on Inquiry into childhood rheumatic diseases.

The list of variants for sickle cell disease, beta thalassemia and other hemoglobinopathies are captured in this resource.

Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1).

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.